Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The concanavalin A-induced agglutination of cultivated cells of human osteosarcoma Sa-4 was studied in the process of their reversion caused by high polar compounds, dimethylsulphoxide (DMSO) and dimethylformamide (DMFA). Primarily lectin induced an expressed ability to agglutination in Sa-4 cells. In the process of tumour cell reversion under the effect of chemical inducers their agglutination decreases. After the DMSO and DMFA removal the osteosarcoma cells return to their initial state showing a high agglutination. Other high-polar compounds (N-methylformamide and dimethylacetamide) induced no reversion of Sa-4 cells and no agglutination of them as well.
 ...
PMID:[Changes in lectin-induced agglutination of human tumor cells during the process of their reversion]. 385

N-methylformamide (NMF), a powerful differentiating agent, has been extensively used in experimental and preclinical cancer chemotherapy studies, alone or in association with conventional anti-cancer drugs. To evaluate the use of this molecule in the treatment of osteosarcoma (OS), we have analyzed the effects of NMF and doxorubicin (DXR) on DXR-sensitive and -resistant human OS cell lines. Our study shows that NMF exerts remarkable effects on cell proliferation and, in Saos-2 and SARG cells, also induces differentiation, as shown by increasing alkaline phosphatase activity. Moreover, NMF increases the cytotoxic activity of DXR when administered after the drug, in both DXR-sensitive and -resistant cells. However, when this agent is given before DXR, it enhances P-glycoprotein expression in U-2 OS cell lines. This over-expression is associated with reduced DXR accumulation within cells and with significant enhancement of resistance to DXR.
 ...
PMID:Pre-treatment of human osteosarcoma cells with N-methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. 791 35